One target, two evidence streams: Rituximab versus ocrelizumab in relapsing multiple sclerosis: A design-stratified systematic review, meta-analysis, and concordance assessment.
- DOI
- 10.1016/j.msard.2026.107934
- Published
- 2026 Sep 19
- Container
- Multiple sclerosis and related disorders
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.msard.2026.107934,
title = {One target, two evidence streams: Rituximab versus ocrelizumab in relapsing multiple sclerosis: A design-stratified systematic review, meta-analysis, and concordance assessment.},
author = {Nabil Y and Shaheen A and Mansour A and Seyed EKA and Alsel BA and Esmaeel SE and Meshref M and Saha R},
year = {2026},
journal = {Multiple sclerosis and related disorders},
doi = {10.1016/j.msard.2026.107934},
url = {https://doi.org/10.1016/j.msard.2026.107934}
}RIS
TY - JOUR TI - One target, two evidence streams: Rituximab versus ocrelizumab in relapsing multiple sclerosis: A design-stratified systematic review, meta-analysis, and concordance assessment. AU - Nabil Y AU - Shaheen A AU - Mansour A AU - Seyed EKA AU - Alsel BA AU - Esmaeel SE AU - Meshref M AU - Saha R PY - 2026 JO - Multiple sclerosis and related disorders DO - 10.1016/j.msard.2026.107934 UR - https://doi.org/10.1016/j.msard.2026.107934 ER -
APA
Y, N., A, S., A, M., EKA, S., BA, A., SE, E., M, M., & R, S. (2026). One target, two evidence streams: Rituximab versus ocrelizumab in relapsing multiple sclerosis: A design-stratified systematic review, meta-analysis, and concordance assessment.. Multiple sclerosis and related disorders. https://doi.org/10.1016/j.msard.2026.107934
Source records
- pubmed · retrieved 2026-09-25T18:17:39.282Z